LONDON – Oxford BioDynamics PLC (LON:), a clinical diagnostics company specializing in precision medicine, announced a retail offer to raise up to £500,000 through a new share issuance. This offering is exclusive to existing eligible shareholders in the United Kingdom (TADAWUL:) and is being conducted via the Winterflood Retail Access Platform (WRAP).
The offering entails up to 100,000,000 new ordinary shares at an issue price of 0.5 pence each. The issue price marks a 44% discount to the closing mid-market price of 0.9 pence per ordinary share on Sunday. The funds raised will be used similarly to the proceeds from a concurrent placing and subscriptions aimed at raising a minimum of £6 million.
The retail offer is part of a broader fundraising strategy by the company, which is contingent upon shareholder approval at a general meeting scheduled for 31 January 2025 and the subsequent admission of the new shares to trading on the AIM market of the London Stock Exchange (LON:). Trading is expected to commence on 4 February 2025.
Oxford BioDynamics is reaching out to its retail shareholder base in the UK, providing an opportunity to participate in the company’s growth. The minimum subscription per investor is set at £250, with the offer set to close at 4:30 pm on Thursday of this week. Shareholders interested in participating may contact their brokers or wealth managers.
The new ordinary shares issued will be fully paid and rank equally with the existing ordinary shares, including the right to receive dividends and other distributions declared after the date of issue.
Investors are reminded that an investment in the company carries risks and capital is at stake. The value of investments can fluctuate, potentially resulting in investors receiving less than their original investment.
This announcement is based on a press release statement and does not constitute an offer or solicitation in jurisdictions where such actions would violate applicable laws. The offering is not being made in the United States, Australia, Canada, New Zealand, Japan, South Africa, any EEA member state, or any jurisdiction where it would be unlawful. The retail offer shares will not be registered under the US Securities Act and are not being offered in the US.
The information provided in this article is for background purposes and does not purport to be full or complete. It is based on a press release statement and should be read in conjunction with the company’s full announcement for a comprehensive understanding of the offer’s terms and conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
